Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06309979 · ClinicalTrials.gov registry record
A Study to Assess Growth in Children With Idiopathic Short Stature
A clinical trial of Idiopathic Short Stature, sponsored by BioMarin Pharmaceutical.
- Recruiting
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT06309979: Recruiting study of Idiopathic Short Stature, sponsored by BioMarin Pharmaceutical.
NCT06309979 is a study of Idiopathic Short Stature that is actively recruiting participants, run by BioMarin Pharmaceutical. The registered enrollment target is 300 participants, above the 113-participant average among 4 other Idiopathic Short Stature trials with a reported enrollment target (165% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06309979, a study of Idiopathic Short Stature, is actively recruiting participants, sponsored by BioMarin Pharmaceutical.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
Conditions Studied
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed) - Los Angeles
- Children's Hospital of Orange County Main Campus - Orange - Orange
- Center Of Excellence in Diabetes and Endocrinology - Sacramento
- Rady Children's Hospital - San Diego - San Diego
- University of California San Francisco (UCSF) - San Francisco
Florida
- Nemours Children's Clinic - Jacksonville
- Nicklaus Children's Hospital - Miami
- Nemours Children's Health System - Corporate Headquarters - Pensacola
Idaho
- St. Luke's Children's Endocrinology - Boise
- Rocky Mountain Diabetes Center - Idaho Falls - Idaho Falls
- Rocky Mountain Clinical Research - Idaho Falls - Idaho Falls
Connecticut
- Connecticut Children's Medical Center - Hartford
- Yale School of Medicine - New Haven
Arizona
- Phoenix Children's Hospital - Thomas Campus (Main) - Phoenix
District of Columbia
- Children's National Health System - Washington D.C.
Georgia
- Centricity Research - Columbus
Kentucky
- University of Louisville School Of Medicine - Norton Children's Hospital - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2040-12-31 |
What NCT06309979 shows while recruiting
NCT06309979 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 113-participant average among 4 other Idiopathic Short Stature trials with a reported enrollment target (165% higher).
The record links to 1 condition, with Idiopathic Short Stature appearing as the primary indexed condition, and to 0 interventions.
NCT06309979 names 20 study sites across 10 states, led by California, Florida, Idaho.
Frequently Asked Questions
What is clinical trial NCT06309979 about?
NCT06309979 is a clinical study titled "A Study to Assess Growth in Children With Idiopathic Short Stature". Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
What is the current status of trial NCT06309979?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-08-08. Estimated completion is 2040-12-31.
What conditions does trial NCT06309979 study?
This clinical trial studies the following conditions: Idiopathic Short Stature.
Who is sponsoring clinical trial NCT06309979?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06309979 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Short Stature
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
RECRUITING · Phase 2
-
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
RECRUITING · Phase 3
-
Genotropin Study Assessing Use of Injection Pen
COMPLETED · Phase 3
-
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI